Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade).

Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade)

BeiGene

Amicus Therapeutics

Novartis

SPDR S&P Biotech ETF

China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.

The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.

AeroVironment

Flex

Graphite Bio

Atlassian

KLA-Tencor

About 600 more tech and biotech layoffs rocked the Bay Area job market in a fresh round of cutbacks that suggest the staffing reductions in the region have yet to run their course, new state government filings show.

Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Marek Ciszewski - SVP, IR Denny Lanfear - CEO Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - CFO Conference Call Participants Salim Syed - Mizuho Douglas Tsao - HC Wainwright Chris Schott - JPMorgan Jason Gerberry - Bank of America Ash Verma - UBS Operator Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to SVP, Investor Relations, Marek Ciszewski.

Coherus BioSciences, Inc. (CHRS) Q4 2022 Earnings Call Transcript

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 – – FDA is planning the toripalimab manufacturing site inspection in Q2 2023 – – UDENYCA® autoinjector approved by FDA; UDENYCA® on-body injector under review by FDA – – Planning underway for potential 2023 commercial launches of toripalimab, YUSIMRY™, UDENYCA® AI and UDENYCA® OBI – – Conference call today at 5 p.m. ET –

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

- UDENYCA® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy -

FDA Approves UDENYCA® Autoinjector

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March.

Coherus BioSciences to Present at Upcoming Investor Conferences in March

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

AbbVie

Alvotech SA

Amgen

Bristol-Myers

Cigna

CVS Health

Fresenius Medical Care

GlaxoSmithKline

Johnson & Johnson

Merck

Novo Nordisk

Organon & Co

Pfizer

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Teva Pharmaceutical

Viatris

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

- Q-Code assigned to CIMERLI ® for Medicare claims processing effective for dates of service on and after April 1, 2023 -

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

Coherus shares are trading at a >35% discount to their 2014 IPO price of $13.5, but I think that can change for the better in 2023. The company's sales of lead commercial asset - a biosimilar of Amgen's Neulasta - are falling in the face of competition.

Coherus BioSciences: Biosimilar Specialist With Approval Shot For Chinese Cancer Drug Looks Like A Buy

Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Coherus BioSciences got its toripalimab launch delayed due to the Chinese pandemic restrictions. However, eventual launch, and especially launch of Humira and Lucentis biosimilar may boost stock.

Coherus: Launch Of Humira Biosimilar May Boost Stock

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/upcoming-events. This webcast will be available for replay until February 10, 2023.

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Marek Ciszewski - Senior Vice President, Investor Relations Denny Lanfear - Chief Executive Officer Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Douglas Tsao - HC Wainwright Georgi Yordanov - Cowen Steve Boland - Bank of America Chris Schott - JPMorgan Ash Verma - UBS Operator Good day and thank you for standing by. Welcome to the Coherus Biosciences Inc. Q3 2022 Conference Call.

Coherus BioSciences, Inc. (CHRS) Q3 2022 Earnings Call Transcript

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates

– UDENYCA® net sales of $45.4 million in the third quarter 2022 – – CIMERLI™ launched in the United States on October 3 rd – – Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and UDENYCA® OBI – – Conference call today at 5 p.m. ET –

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022. Starting at 5:00 p.m. Eastern Time on November 8, 2022, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. The press release with the third quarter 2022 financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ®  (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity -

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022

REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET.

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

Coherus BioSciences (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing

Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock.

Coherus: 2022 Is In Many Ways A Make Or Break Year

The average of price targets set by Wall Street analysts indicates a potential upside of 47.3% in Coherus BioSciences (CHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Marek Ciszewski – Investor Relations Denny Lanfear – Chief Executive Officer Rosh Dias – Chief Medical Officer Paul Reider – Chief Commercial Officer McDavid Stilwell – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Company Douglas Tsao – H.C. Wainwright & Company Jason Gerberry – Bank of America Ash Verma – UBS Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q2 2022 Coherus BioSciences, Inc. Earnings Conference Call.

News for Coherus BioSciences Stock (CHRS)